Abstract
Current machine learning-based Alzheimer’s disease (AD) diagnosis methods fail to explore the distinctive brain patterns across different AD stages, lacking the ability to trace the trajectory of AD progression. This limitation can lead to an oversight of the pathological mechanisms of AD and suboptimal performance in AD diagnosis. To overcome this challenge, this paper proposes a novel stage-aware brain graph learning model. Particularly, we analyze the different brain patterns of each AD stage in terms of stage-specific brain graphs. We design a Stage Feature-enhanced Graph Contrastive Learning method, named SF-GCL, utilizing specific features within each AD stage to perform graph augmentation, thereby effectively capturing differences between stages. Significantly, this study unveils the specific brain patterns corresponding to each AD stage, showing great potential in tracing the trajectory of brain degeneration. Experimental results on a real-world dataset demonstrate the superiority of our model.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at the AD Neuroimaging Initiative database
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
